Find MND Biomarker

Welcome to FindMNDBiomarker, an integrative database that consolidates the proteomic findings in brain tissue and biofluids (CSF and blood) from patients with motor neuron disease (also known as amyotrophic lateral sclerosis). FightMNDBiomarker is designed for users to quickly assess whether their proteins of interest have been identified in other cohorts and biosamples from patients with MND/ALS.

Purpose: The goal of this search platform is to facilitate the comparison and discovery of proteins that may serve as promising and reproducible biofluid biomarkers of brain-specific changes in MND/ALS and to identify markers that should be further targeted for analyses and validation.

Using this database: Searches can be performed by entering the protein UniProt IDs, names and sample types into the relevant search term box using free text entry. For example, entering ‘NEFL’ will generate a list of all publications in which NEFL was identified to be significantly dysregulated.

A searchable and filterable table is provided with the following columns:

Name: Gene name corresponding to the UniProt ID
UniProt ID: UniProt accession number
Publication: Study Reference
Condition: e.g.ALS – Control, ALS Fast – ALS Slow
Sample Type: Sample type used (Abbreviations: SMNs, single motor neurons; AH, anterior horn; PH, posterior horn)
Regulation: Direction of change (upregulated or downregulated)
Cohorts: Cohort size used for each study
Average age at onset ± standard deviation/age range: Average age at onset of ALS cohorts with standard deviation or age range (if provided by publication)
Average age at collection ± standard deviation/age range: Average age at collection of ALS cohorts with standard deviation or age range (if provided by publication)
Average PMI (range) (hours): Average postmortem interval with range (if provided by tissue studies)

To cite this database: Further details and application of this search tool are described in our manuscript “title” that can be located with this DOI: _____

Contact: For help contact rachel.tan1@sydney.edu.au

Biomarker Name

UniProt ID

Condition

Publication

Sample Type

Sort by:

Ascending Descending

Total Records Found: 2896, showing 100 per page
Biomarker Name	UniProt ID	Publication	Condition	Sample Type	Regulation	Cohorts	Average age at onset	Average age at collection	Average PMI
DBN1	Q16643	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
DBI	P07108	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
DBI	P07108	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
DBI	P07108	Seyfried et al. 2018	ALS – Control	Prefrontal cortex	Down	8 ALS, 8 control	60	63.5	9.1
DARS1	P14868	Guise et al. 2023	ALS – Control	Spinal cord (SMNs)	Down	3 ALS, 3 control		69.3	9.2
DAG1	Q14118	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
DAAM1	Q9Y4D1	Oeckl et al. 2020	ALS – Control	Spinal cord	Down	8 ALS, 7 control		59 (52-61)	36 (24-90)
DAAM1	Q9Y4D1	Seyfried et al. 2018	ALS – Control	Prefrontal cortex	Up	8 ALS, 8 control	60	63.5	9.1
CYTH3	O43739	Seyfried et al. 2018	ALS – Control	Prefrontal cortex	Up	8 ALS, 8 control	60	63.5	9.1
CYR61	O00622	Zhou et al. 2023	SO-ALS – Control	CSF	Up	4 BO-ALS, 5 SO-ALS, 5 control	63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS)	64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS)
CYFIP2	E7EVJ5	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
CYCS	P99999	Guise et al. 2023	ALS – Control	Spinal cord (SMNs)	Down	3 ALS, 3 control		69.3	9.2
CYCS	C9JFR7	Bereman et al. 2018	ALS – Control	CSF	Down	33 ALS, 30 control
CYCS	P99999	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
CYC1	P08574	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
CYBB	P04839	Oeckl et al. 2020	ALS – Control	Spinal cord	Up	8 ALS, 7 control		59 (52-61)	36 (24-90)
CYBA	P13498	Oeckl et al. 2020	ALS – Control	Spinal cord	Up	8 ALS, 7 control		59 (52-61)	36 (24-90)
CYB5R1	Q9UHQ9	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
CXorf36	Q9H7Y0	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
CXCL3	P19876	Berrone et al. 2023	fALS – Control	Plasma	Up	8 fALS, 8 control	62 ± 13 (sALS & fALS)	64 ± 11 (sALS & fALS)
CXCL3	P19876	Berrone et al. 2023	ALS – Control	Plasma	Up	16 ALS, 8 control	62 ± 13 (sALS & fALS)	64 ± 11 (sALS & fALS)
CXCL16	Q9H2A7	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
CXCL12	Q8UUJ9	Berrone et al. 2023	sALS – Control	Plasma	Up	8 sALS, 8 control	62 ± 13 (sALS & fALS)	64 ± 11 (sALS & fALS)
CUTA	O60888	Iridoy et al. 2019	ALS – Control	Spinal cord (AH)	Up	9 ALS, 8 control	57.6	62.8
CTSS	P25774	Zhou et al. 2023	SO-ALS – Control	CSF	Down	4 BO-ALS, 5 SO-ALS, 5 control	63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS)	64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS)
CTSS	P25774	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
CTSH	P09668	Oeckl et al. 2020	ALS – Control	Spinal cord	Up	8 ALS, 7 control		59 (52-61)	36 (24-90)
CTSH	P09668	Katzeff et al. 2020	ALS – Control	Serum	Up	28 ALS, 22 control		52.7
CTSD	P07339	Zubiri et al. 2018	ALS fast – ALS slow (late stage)	Plasma	Down	8 ALS-fast, 6 ALS-slow	61.3 (48-67) (ALS-fast), 58.1 (35-71) (ALS-slow)
CTSD	P07339	Collins et al. 2015	ALS – Control	CSF	Down	90 ALS, 80 control
CTSB	P07858	Collins et al. 2015	ALS – Control	CSF	Down	90 ALS, 80 control
CTSB	P07858	Guise et al. 2023	ALS – Control	Spinal cord (SMNs)	Down	3 ALS, 3 control		69.3	9.2
CTNNB1	B4DGU4	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
CTNNA2	P26232	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Down	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
CTNNA1	P35221	Oeckl et al. 2020	ALS – Control	Spinal cord	Up	8 ALS, 7 control		59 (52-61)	36 (24-90)
CTGF	P29279	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
CTBS	Q01459	Collins et al. 2015	ALS – Control	CSF	Down	90 ALS, 80 control
CTBP2	P56545	Oeckl et al. 2020	ALS – Control	Spinal cord	Up	8 ALS, 7 control		59 (52-61)	36 (24-90)
CSTB	P04080	Iridoy et al. 2019	ALS – Control	Spinal cord (AH)	Up	9 ALS, 8 control	57.6	62.8
CSTB	P04080	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
CSTB	P04080	Leoni et al. 2019	BO-ALS – LO-ALS	PBMCs	Down	12 BO-ALS, 12 LO-ALS	(39-76) (BO-ALS), (33-81) (LO-ALS)
CSTB	P04080	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
CST6	Q15828	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
CST3	P01034	Iridoy et al. 2019	ALS – Control	Spinal cord (AH)	Down	9 ALS, 8 control	57.6	62.8
CST3	P01034	Collins et al. 2015	ALS – Control	CSF	Down	90 ALS, 80 control
CST1	P01037	Oeckl et al. 2020	gALS – Control	CSF	Up	14 gALS, 16 control	54 (52-69)	62 (53-75)
CSRP3	P50461	Berrone et al. 2023	ALS – Control	Plasma	Up	16 ALS, 8 control	62 ± 13 (sALS & fALS)	64 ± 11 (sALS & fALS)
CSRP3	P50461	Berrone et al. 2023	fALS – Control	Plasma	Up	8 fALS, 8 control	62 ± 13 (sALS & fALS)	64 ± 11 (sALS & fALS)
CSRP1	P21291	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
CSPG4	Q6UVK1	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
CSH	P01243	Chen et al. 2016	ALS – Control	CSF	Down	35 ALS, 10 control		52.7 ±12.13
CSF3R	Q99062	Berrone et al. 2023	sALS – Control	Plasma	Up	8 sALS, 8 control	62 ± 13 (sALS & fALS)	64 ± 11 (sALS & fALS)
CSF2RA	P15509	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
CRYZL1	A6NMA8	Seyfried et al. 2018	ALS – Control	Prefrontal cortex	Up	8 ALS, 8 control	60	63.5	9.1
CRYZ	Q08257	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
CRYM	Q14894	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
CRYL1	Q9Y2S2	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Down	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
CRYBG3	Q68DQ2	Collins et al. 2015	ALS – Control	CSF	Up	90 ALS, 80 control
CRYAB	P02511	Oeckl et al. 2020	ALS – Control	CSF	Up	26 ALS, 16 control
CRYAB	P02511	Oeckl et al. 2020	sALS – Control	CSF	Up	12 ALS, 16 control	66 (57-68)	67 (58-74)
CRYAB	P02511	Iridoy et al. 2019	ALS – Control	Spinal cord (AH)	Up	9 ALS, 8 control	57.6	62.8
CRYAB	P02511	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Up	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
CRYAB	P02511	Oeckl et al. 2020	gALS – Control	CSF	Up	14 gALS, 16 control	54 (52-69)	62 (53-75)
CRTAC1	Q9NQ79	Collins et al. 2015	ALS – Control	CSF	Down	90 ALS, 80 control
CRTAC1	Q9NQ79	Katzeff et al. 2020	ALS – Control	Serum	Down	28 ALS, 22 control		52.7
CRP	P02741	Oeckl et al. 2020	gALS – Control	CSF	Up	14 gALS, 16 control	54 (52-69)	62 (53-75)
CRP	P02741	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
CRKL	P46109	Iridoy et al. 2019	ALS – Control	Spinal cord (AH)	Down	9 ALS, 8 control	57.6	62.8
CRK	P46108	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
CRISP3	P54108	Vu et al. 2023	ALS fast – ALS slow	CSF	Up	6 ALS-fast, 5 ALS-slow	54.3 (ALS-fast), 43.4 (ALS-slow)	55.3 (ALS-fast), 52.2 (ALS-slow)
CRIP2	H0YFA4	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
CRIP2	P52943	Seyfried et al. 2018	ALS – Control	Prefrontal cortex	Down	8 ALS, 8 control	60	63.5	9.1
CPXM1	Q96SM3	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
CPQ	Q9Y646	Collins et al. 2015	ALS – Control	CSF	Down	90 ALS, 80 control
CPPED1	Q9BRF8	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
CPNE6	O95741	Guise et al. 2023	ALS – Control	Spinal cord (SMNs)	Down	3 ALS, 3 control		69.3	9.2
CPNE5	Q9HCH3	Seyfried et al. 2018	ALS – Control	Prefrontal cortex	Up	8 ALS, 8 control	60	63.5	9.1
CPNE4	Q96A23	Oeckl et al. 2020	ALS – Control	Spinal cord	Down	8 ALS, 7 control		59 (52-61)	36 (24-90)
CPNE4	Q96A23	Leoni et al. 2019	BO-ALS – LO-ALS	PBMCs	Down	12 BO-ALS, 12 LO-ALS	(39-76) (BO-ALS), (33-81) (LO-ALS)
CPNE1	Q99829	Berrone et al. 2023	fALS – Control	Plasma	Up	8 fALS, 8 control	62 ± 13 (sALS & fALS)	64 ± 11 (sALS & fALS)
CPN2	Q96KN2	Vu et al. 2023	ALS fast – ALS slow	CSF	Up	6 ALS-fast, 5 ALS-slow	54.3 (ALS-fast), 43.4 (ALS-slow)	55.3 (ALS-fast), 52.2 (ALS-slow)
CPN2	P22792	Xu et al. 2018	ALS – Control	Plasma	Up	42 ALS, 18 control		61.8 ± 9.6
CPN1	P15169	Vu et al. 2023	ALS fast – ALS slow	CSF	Up	6 ALS-fast, 5 ALS-slow	54.3 (ALS-fast), 43.4 (ALS-slow)	55.3 (ALS-fast), 52.2 (ALS-slow)
CPN1	P15169	Zubiri et al. 2018	ALS fast – ALS slow (early stage)	Plasma	Up	8 ALS-fast, 6 ALS-slow	61.3 (48-67) (ALS-fast), 58.1 (35-71) (ALS-slow)
CPN1	P15169	Zubiri et al. 2018	Late ALS – Early ALS (ALS fast cohort)	Plasma	Up	8 ALS-fast, 6 ALS-slow	61.3 (48-67) (ALS-fast), 58.1 (35-71) (ALS-slow)
CPN1	P15169	Zubiri et al. 2018	Late ALS – Early ALS (ALS slow cohort)	Plasma	Up	8 ALS-fast, 6 ALS-slow	61.3 (48-67) (ALS-fast), 58.1 (35-71) (ALS-slow)
CPN1	P15169	Oeckl et al. 2020	gALS – Control	CSF	Up	14 gALS, 16 control	54 (52-69)	62 (53-75)
CPLX1	O14810	Oeckl et al. 2020	ALS – Control	CSF	Up	26 ALS, 16 control
CPLX1	O14810	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
CPLX1	D6RI11	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Down	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
CPB2	Q96IY4	Vu et al. 2023	ALS fast – ALS slow	CSF	Up	6 ALS-fast, 5 ALS-slow	54.3 (ALS-fast), 43.4 (ALS-slow)	55.3 (ALS-fast), 52.2 (ALS-slow)
CPB2	Q96IY4	Zubiri et al. 2018	ALS fast – ALS slow (early stage)	Plasma	Down	8 ALS-fast, 6 ALS-slow	61.3 (48-67) (ALS-fast), 58.1 (35-71) (ALS-slow)
CPB2	Q96IY4	Zubiri et al. 2018	Late ALS – Early ALS (ALS fast cohort)	Plasma	Up	8 ALS-fast, 6 ALS-slow	61.3 (48-67) (ALS-fast), 58.1 (35-71) (ALS-slow)
CPB2	Q96IY4	Bereman et al. 2018	ALS – Control	CSF	Up	33 ALS, 30 control
CPB2	A0A087WSY5	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
CPB1	P15086	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
CPAMD8	Q8IZJ3	Collins et al. 2015	ALS – Control	CSF	Up	90 ALS, 80 control
CP	P00450	Vu et al. 2023	ALS fast – ALS slow	CSF	Up	6 ALS-fast, 5 ALS-slow	54.3 (ALS-fast), 43.4 (ALS-slow)	55.3 (ALS-fast), 52.2 (ALS-slow)
CP	P00450	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Down	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
CP	P00450	Iridoy et al. 2019	ALS – Control	Spinal cord (AH)	Up	9 ALS, 8 control	57.6	62.8